SCHEMBL513467

SCHEMBL513467

CCC(CC)(c1noc(-c2ccccn2)n1)P(=O)(O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.42
FAAH O00519 1/20 0.41
CES1 P23141 1/20 0.41
RAB9A P51151 9/20 0.40
NPC1 O15118 9/20 0.40
SMN1; SMN2 Q16637 7/20 0.40
HTT P42858 1/20 0.40
S1PR1 P21453 1/20 0.40
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
POLB P06746 1/20 0.40
PKM P14618 8/20 0.39
TP53 P04637 6/20 0.39
HPGD P15428 3/20 0.39
GAA P10253 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL513461 0.82 CCR1 (0.37) HSD17B10RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL513204 0.82 HDAC6 (0.44) HSD17B10RAB9ANPC1SMN1; SMN2S1PR1
SCHEMBL513425 0.78 NPC1 (0.45) HSD17B10RAB9ANPC1SMN1; SMN2HTT
SCHEMBL513221 0.77 CHRNB2 (0.49) HSD17B10RAB9ANPC1SMN1; SMN2HTT
SCHEMBL512093 0.76 NPC1 (0.41) HSD17B10RAB9ANPC1SMN1; SMN2HTT
SCHEMBL513443 0.75 NPC1 (0.44) HSD17B10RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL513092 0.74 NPC1 (0.46) HSD17B10RAB9ANPC1SMN1; SMN2S1PR1
SCHEMBL513589 0.73 NPC1 (0.47) RAB9ANPC1SMN1; SMN2PKMTP53
SCHEMBL513254 0.73 TP53 (0.45) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL512821 0.72 CA2 (0.41) RAB9ANPC1ALDH1A1KDM4ECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 HSD17B10 3593/4885FAAH 215/4885CES1 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.